Novo Nordisk Valuation
Is NOVOB N undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NOVOB N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NOVOB N (MX$2203.3) is trading below our estimate of fair value (MX$2605.07)
Significantly Below Fair Value: NOVOB N is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NOVOB N?
Key metric: As NOVOB N is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is NOVOB N's PE Ratio? | |
|---|---|
| PE Ratio | 33.3x |
| Earnings | DKK 94.72b |
| Market Cap | DKK 3.15t |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 11.6x |
| Enterprise Value/EBITDA | 24.6x |
| PEG Ratio | 2.3x |
Price to Earnings Ratio vs Peers
How does NOVOB N's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 34.8x | ||
LAB B Genomma Lab Internacional. de | 15.7x | 20.0% | Mex$25.2b |
LLY Eli Lilly | 78.2x | 29.5% | US$671.9b |
JNJ Johnson & Johnson | 25.2x | 10.6% | US$370.8b |
MRK Merck | 20.1x | 15.6% | US$243.6b |
NOVOB N Novo Nordisk | 33.3x | 14.4% | Mex$3.2t |
Price-To-Earnings vs Peers: NOVOB N is good value based on its Price-To-Earnings Ratio (33.3x) compared to the peer average (35.3x).
Price to Earnings Ratio vs Industry
How does NOVOB N's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
| 26 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 26 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: NOVOB N is expensive based on its Price-To-Earnings Ratio (33.3x) compared to the Global Pharmaceuticals industry average (22.8x).
Price to Earnings Ratio vs Fair Ratio
What is NOVOB N's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 33.3x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NOVOB N's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$2,203.30 | Mex$2,699.15 +22.5% | 20.3% | Mex$3,309.04 | Mex$1,611.36 | n/a | 24 |
| Nov ’25 | Mex$2,248.29 | Mex$2,729.77 +21.4% | 20.4% | Mex$3,323.40 | Mex$1,618.35 | n/a | 24 |
| Oct ’25 | n/a | Mex$2,793.48 0% | 20.3% | Mex$3,381.43 | Mex$1,646.61 | n/a | 25 |
| Sep ’25 | Mex$2,643.43 | Mex$2,640.51 -0.1% | 20.1% | Mex$3,332.54 | Mex$1,555.19 | n/a | 26 |
| Aug ’25 | n/a | Mex$2,623.20 0% | 18.7% | Mex$3,259.80 | Mex$1,521.24 | n/a | 26 |
| Jul ’25 | n/a | Mex$2,517.77 0% | 18.3% | Mex$3,173.15 | Mex$1,480.80 | n/a | 26 |
| Jun ’25 | Mex$2,226.00 | Mex$2,263.84 +1.7% | 18.5% | Mex$2,764.07 | Mex$1,308.00 | n/a | 26 |
| May ’25 | n/a | Mex$2,147.26 0% | 19.4% | Mex$2,659.73 | Mex$1,258.62 | n/a | 25 |
| Apr ’25 | Mex$2,098.65 | Mex$2,142.11 +2.1% | 19.6% | Mex$2,682.90 | Mex$1,269.59 | n/a | 25 |
| Mar ’25 | Mex$2,067.45 | Mex$2,029.37 -1.8% | 16.8% | Mex$2,425.10 | Mex$1,311.53 | n/a | 24 |
| Feb ’25 | n/a | Mex$1,920.92 0% | 18.5% | Mex$2,441.95 | Mex$1,121.30 | n/a | 23 |
| Jan ’25 | Mex$1,743.50 | Mex$1,812.41 +4.0% | 20.4% | Mex$2,200.33 | Mex$905.28 | n/a | 23 |
| Dec ’24 | Mex$1,704.83 | Mex$1,785.21 +4.7% | 20.2% | Mex$2,195.91 | Mex$903.46 | n/a | 23 |
| Nov ’24 | n/a | Mex$1,732.84 0% | 21.1% | Mex$2,091.65 | Mex$912.72 | Mex$2,248.29 | 22 |
| Oct ’24 | n/a | Mex$1,602.96 0% | 19.7% | Mex$2,001.38 | Mex$889.50 | n/a | 22 |
| Sep ’24 | n/a | Mex$1,533.94 0% | 18.1% | Mex$1,922.72 | Mex$893.13 | Mex$2,643.43 | 22 |
| Aug ’24 | Mex$1,358.51 | Mex$1,473.20 +8.4% | 15.8% | Mex$1,831.60 | Mex$909.49 | n/a | 23 |
| Jul ’24 | n/a | Mex$1,460.11 0% | 16.2% | Mex$1,828.10 | Mex$907.75 | n/a | 22 |
| Jun ’24 | Mex$1,442.27 | Mex$1,458.71 +1.1% | 16.8% | Mex$1,840.80 | Mex$914.05 | Mex$2,226.00 | 22 |
| May ’24 | Mex$1,493.45 | Mex$1,480.81 -0.8% | 19.5% | Mex$1,920.40 | Mex$900.60 | n/a | 22 |
| Apr ’24 | Mex$1,371.09 | Mex$1,359.90 -0.8% | 18.6% | Mex$1,651.22 | Mex$905.51 | Mex$2,098.65 | 22 |
| Mar ’24 | Mex$1,290.00 | Mex$1,270.42 -1.5% | 17.0% | Mex$1,582.73 | Mex$882.18 | Mex$2,067.45 | 23 |
| Feb ’24 | Mex$1,327.80 | Mex$1,302.71 -1.9% | 18.3% | Mex$1,644.25 | Mex$739.91 | n/a | 23 |
| Jan ’24 | n/a | Mex$1,260.11 0% | 15.4% | Mex$1,520.60 | Mex$756.80 | Mex$1,743.50 | 23 |
| Dec ’23 | n/a | Mex$1,182.62 0% | 15.9% | Mex$1,470.65 | Mex$731.94 | Mex$1,704.83 | 24 |
| Nov ’23 | n/a | Mex$1,128.10 0% | 15.6% | Mex$1,417.88 | Mex$715.57 | n/a | 25 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
ROVI N
€1,416.38
7D
0%
1Y
54.7%
ICON
US$15.7b
A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
ICLR N
US$4,286.08
7D
3.3%
1Y
-7.7%
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%